Published May 7, 2022
“AI applied to hit identification and de novo molecular design can explore real vast areas of chemical space, and generate molecules that can actually be synthesized in the laboratory”
-Explained Grant Wishart, Director of Computer-Aided Drug Design at Charles River Laboratories.
AI has the ability to make complex drug development procedures faster and more cost-effective, with the goal of lowering the time it takes for a new treatment to reach a patient. The life sciences business is paying more attention to AI because of the optimism surrounding it.
AI has been successfully utilized to discover prospective medications that could be used to treat Covid-19 in the present pandemic. AlphaFold, a Google Deepmind AI system, recently discovered a solution to how proteins fold into their 3D shape, potentially opening up new avenues in structure-based medication creation.
Given that AI can aid rational drug design , assist in decision making, determine the right therapy for a patient, including personalized medicines, and manage clinical data generated and use it for future drug development , AI's involvement in the development of a pharmaceutical product from the bench to the bedside can be imagined. Eularis' E-VAI platform is an analytical and decision-making AI platform that uses machine learning algorithms and an easy-to-use user interface to create analytical roadmaps based on competitors, key stakeholders, and current market share to predict key drivers in pharmaceutical sales, allowing marketing executives to allocate resources for maximum market share gain, reversing poor sales, and anticipating where to invest.
AI can interpret lives of many, and also various industries through the potentials it holds within its accurate models, techniques promising a better future for the humanity race.